Trial Profile

A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants with Metastatic or Unresectable Solid Tumors with HER2-activating Mutations

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sevabertinib (Primary)
Indications Biliary cancer; Bladder cancer; Carcinoma; Cervical cancer; Colon cancer; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Rectal cancer; Solid tumours; Urogenital cancer
Focus Therapeutic Use
Acronyms panSOHO
Sponsors Bayer

03 Sep 2026 Planned End Date changed from 25 Oct 2027 to 26 Oct 2029.
03 Sep 2026 Planned primary completion date changed from 3 Feb 2027 to 2 Feb 2029.
18 Feb 2025 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com